DMT, Ayahuasca, 5-Me-O-DMT & emerging enactogens

🧠 Depression

1. 🆕 📄 Title: Phase 2 RECONNECT Trial: RE104 for Postpartum Depression, Reunion Neuroscience Press Release (2025)
   👥 Authors: Reunion Neuroscience clinical team (press release; not peer-reviewed)
   🔗 Link:  https://reunionneuro.com/2025/08/18/reunion-neuroscience-announces-positive-topline-results-from-reconnect-phase-2-clinical-trial-of-re104-for-the-treatment-of-postpartum-depression-ppd/
   📌 Note: Emerging Evidence — Results from company press release; peer-reviewed publication pending.

🧠 Summary: This press release reports topline results from the RECONNECT Phase 2 trial evaluating RE104, a prodrug of a proprietary psilocybin analog, for moderate-to-severe postpartum depression (PPD). A single 30 mg subcutaneous dose of RE104 was compared to an inactive 1.5 mg control in a randomized, double-blind study.

📊 Results:

• Primary endpoint achieved:

  • 23.0-point reduction in MADRS score at Day 7 in the RE104 group

  • 17.2-point reduction in the control group

  • Difference: 5.8 points (p = 0.0094)

• Rapid and durable efficacy:

  • 77.1% met clinical response criteria (≥50% MADRS reduction) by Day 7

  • 71.4% met remission criteria (MADRS ≤10) by Day 7

  • Improvements were maintained through Day 28

  • Functional and maternal bonding improvements also reported

• Safety:

  • No serious adverse events

  • 92.7% were discharge-ready within 4 hours post-dosing

  • Lactation data suggest minimal drug transfer into breast milk

✅ Conclusion: This Phase 2 trial suggests that a single dose of RE104 produces rapid, clinically meaningful, and durable improvements in postpartum depression with an encouraging safety profile. If replicated in Phase 3, RE104 may represent a scalable, fast-acting treatment for PPD—one of the most urgent and undertreated perinatal conditions.

📌 Pending peer-reviewed publication; findings based on company-released topline data.

🧪 Addiction

💥 Trauma / PTSD

1. 🎖️ 📄 Title: The VA Prescribed a Cocktail of Drugs to Veterans. Many Died by Suicide, Wall Street Journal 2024
   👥 Author: Michael M. Phillips
   🔗 Link: Read Full Article on WSJ

🧠 Summary: This in-depth Wall Street Journal investigation reveals the VA’s long-standing practice of prescribing complex and often dangerous psychiatric drug combinations to veterans suffering from PTSD, chronic pain, depression, and anxiety. Many veterans were placed on multiple high-risk medications simultaneously, including opioids, benzodiazepines, antipsychotics, and sedatives—despite internal warnings and guidelines discouraging such polypharmacy. The article details tragic outcomes including suicide and functional decline. Importantly, it highlights a growing interest among veterans in psychedelic therapies, particularly ibogaine and 5-MeO-DMT, as potential life-saving alternatives to these failed pharmaceutical regimens.

📊 Results:  The article documents how veterans subjected to heavy medication cocktails often experienced emotional numbing, mental deterioration, and increased suicidal ideation. Several high-profile deaths are chronicled. In parallel, it notes a surge in veteran-led interest in psychedelic-assisted therapies, particularly ibogaine—cited for its potential to interrupt addiction—and 5-MeO-DMT, noted for its rapid-acting and intense therapeutic effects. Though these substances remain largely inaccessible through the VA, some veterans are independently seeking out treatments abroad or through underground networks, reporting significant psychological breakthroughs.

✅ Conclusion: The VA’s medication-heavy approach to mental health has contributed to a preventable suicide crisis among veterans. There is an urgent need to re-evaluate treatment models and explore promising alternatives like ibogaine and 5-MeO-DMT, especially given their growing support within the veteran community. These compounds may offer a radical shift away from polypharmacy toward more durable, transformative healing—if regulatory and institutional barriers can be addressed.

🔁 OCD

😰 Anxiety

🍽️ Eating Disorders

🧍‍♂️ Personality Disorders

🔥 Chronic Pain

📚 Evidence & Citation Policy

All research summaries on this site are based on peer-reviewed studies, clinical trials, meta-analyses, and systematic reviews. Each study includes citation details with direct hyperlinks to PubMed or the publishing journal. While we strive for accuracy, readers are encouraged to review the source materials directly. This site does not offer medical advice; for treatment decisions, please consult a licensed clinician.